# SABR-SYNC (NCT05717166)

> A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05717166
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: David Palma
- Conditions: Metastatic Tumor
- Interventions: Palliative Radiotherapy; Chemotherapy; Hormone therapy; Immunotherapy; Targeted Systemic Therapy; Observation; Stereotactic Ablative Radiotherapy; Surgery; Radiofrequency Therapy (RFA); Fractionated Radiation
- Enrollment: 180
- Primary outcome: Overall Survival

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 12
- YouTube: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=sabr-sync-nct05717166

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05717166", "email": "<work email>"}; the inbox owner confirms by the emailed link.